Clinical Trials Sponsored by Global Kinetics Corporation

Total 71 results

Global Kinetics Corporation

Active, not recruiting

Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status (APPRISE)

Parkinson Disease

United States
Global Kinetics Corporation

Terminated

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG (TARGET-PD)

Parkinson Disease

United States
Global Kinetics Corporation

Recruiting

Personal KinetiGraph® Clinical Validation Study

Parkinson Disease | Movement Disorders

United States
Global Kinetics Corporation

Withdrawn

Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG (TARGET-PwP)

Parkinson Disease
Targeted Genetics Corporation

Completed

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

Rheumatoid Arthritis

Canada, United States
Targeted Genetics Corporation

Completed

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

Arthritis, Rheumatoid | Arthritis, Psoriatic | Ankylosing Spondylitis

United States
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Medicis Global Service Corporation

Unknown

Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit

Facial Volume

United States
Medicis Global Service Corporation

Completed

Combination Treatment for Moderate to Severe Acne

Acne

United States
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Cruris

Tinea Cruris

United States, Puerto Rico, Honduras, El Salvador, Belize
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Pedis

Tinea Pedis

United States, Belize
Medicis Global Service Corporation

Completed

Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles

Peri-oral Wrinkles

United States
Medicis Global Service Corporation

Completed

Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Medicis Global Service Corporation

Completed

Safety/Efficacy Study of Restylane® in Lip Augmentation

Lip Augmentation

United States
Global United Pharmaceutical Corporation

Not yet recruiting

Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults (CREWS01)

Asthma

United States
Medicis Global Service Corporation

Completed

Safety and Efficacy Study to Treat Bacterial Vaginosis

Bacterial Vaginosis

United States
Medicis Global Service Corporation

Unknown

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

Actinic Keratosis

United States
General Genetics Corporation
Syntactx

Unknown

Pharmacogenomic Testing Of the Elderly To Reduce Morbidity (POETRY)

Genetics of Drug Metabolism

United States, Puerto Rico
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT)

Melanoma | Breast Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumors

United States
NewLink Genetics Corporation

Completed

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

Healthy

Canada
NewLink Genetics Corporation

Terminated

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

Pancreatic Cancer | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

Pancreatic Cancer | Locally Advanced Malignant Neoplasm | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)

Healthy

United States
NewLink Genetics Corporation

Completed

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
NewLink Genetics Corporation

Terminated

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Melanoma

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal Cancer

United States
NewLink Genetics Corporation

Completed

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
NewLink Genetics Corporation

Completed

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
NewLink Genetics Corporation

Completed

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation, Ukraine
NewLink Genetics Corporation

Completed

Vaccine Treatment for Advanced Malignant Melanoma

Malignant Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Hormone Refractory Prostate Cancer

Prostate Cancer

United States
NewLink Genetics Corporation

Completed

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Metastatic Renal Cell Carcinoma

Korea, Republic of, United States
NewLink Genetics Corporation

Terminated

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Malignant Brain Tumor

United States
NewLink Genetics Corporation

Terminated

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
NewLink Genetics Corporation

Withdrawn

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Cancer | Ovarian Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Malignancy

United States
NewLink Genetics Corporation

Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Malignant Brain Tumor | Primary CNS Tumor

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Solid Tumors

United States
NewLink Genetics Corporation

Completed

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Poland

Clinical Trials Sponsored by Global Kinetics Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations